Vasopressin for Septic Shock Pragmatic Trial
Key facts
- Who runs it
- Intermountain Health Care, Inc.
- Where
- American Fork, Burley, Cedar City, Layton, Logan, Murray, Ogden, Park City, Provo, Riverton, Salt Lake City, Sandy City, and St. George, United StatesSee the 13 sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 3,959 people enrolled
- Started
- 1 Feb 2024
- Ended
- 6 Jun 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Vasopressin
- Recommendation to use a lower initiation threshold for vasopressin
- Recommendation to use a higher initiation threshold for vasopressin
- Record updated
- 3 August 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Age ≥18 years
- Admitted to a study hospital emergency department (ED) or inpatient care unit
- Administration of vasopressor(s) for septic shock
Where in United States
- American Fork HospitalAmerican Fork, United States
- Cassia Regional HospitalBurley, United States
- Cedar City HospitalCedar City, United States
- Layton HospitalLayton, United States
- Logan Regional HospitalLogan, United States
- Intermountain Medical CenterMurray, United States
- McKay-Dee HospitalOgden, United States
- Park City HospitalPark City, United States
- Utah Valley HospitalProvo, United States
- Riverton HospitalRiverton, United States
- LDS HospitalSalt Lake City, United States
- Alta View HospitalSandy City, United States
- St. George Regional HospitalSt. George, United States
About the trial
What the trial wants to find out
Life-threatening low blood pressure due to a serious infection is called "septic shock." Septic shock is treated with vasopressors, medications that raise blood pressure. Sometimes first-line vasopressors are inadequate, prompting addition of a second-line vasopressor called vasopressin. However, the threshold at which to start vasopressin remains unclear. This pragmatic, cluster-randomized, cluster-crossover trial will evaluate two different strategies for septic shock treatment commonly used in current practice, comparing a lower versus a higher threshold for adding vasopressin to first-line vasopressors.
The 2 groups in the trial
- Septic shock treatment strategy involving a lower threshold for vasopressin initiationExisting treatment, for comparison
Recommended strategy for treatment of septic shock includes initiation of fixed-dose IV vasopressin (1.8 units/hour) as a second-line vasopressor if the combined norepinephrine-equivalent dose of other vasopressors reaches ≥0.1 micrograms/kilogram/minute (mcg/kg/min). Use of the recommended treatment strategy (via entry of an order for threshold-based vasopressin initiation) or an alternative treatment strategy is at the discretion of patients' treating clinical team.
Treatment: Vasopressin and Recommendation to use a lower initiation threshold for vasopressin
- Septic shock treatment strategy involving a higher threshold for vasopressin initiationExisting treatment, for comparison
Recommended strategy for treatment of septic shock includes initiation of fixed-dose IV vasopressin (1.8 units/hour) as a second-line vasopressor if the combined norepinephrine-equivalent dose of other vasopressors reaches ≥0.4 mcg/kg/min. Use of the recommended treatment strategy (via entry of an order for threshold-based vasopressin initiation) or an alternative treatment strategy is at the discretion of patients' treating clinical team.
Treatment: Vasopressin and Recommendation to use a higher initiation threshold for vasopressin
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- Record updated
- 3 August 2026